Background Investigations into the rivaroxaban response from the perspective of genetic
variation have been relatively recent and wide in scope, whereas there is no consensus on …

Herba Erigerontis injection (HEI) is an aqueous solution derived from whole plants of
Erigeron breviscapus, which may be co‐administered with warfarin to treat cardiovascular …

Background: The purpose of this study was to identify genetic variations associated with the
metabolism of dabigatran in healthy Chinese subjects, with particular focus given to …

Introduction Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for
stroke prevention in patients with atrial fibrillation (AF). Since NOACs are predominantly …

Background Direct oral anticoagulants, such as apixaban, are increasingly used in everyday
practice in order to treat or prevent thromboembolic diseases. To date, there is no available …

Objectives Apixaban, a direct oral anticoagulant, is increasingly used worldwide for the
treatment and prevention of venous thromboembolism and ischemic stroke in patients with …

Rivaroxaban is an oral anticoagulant directly inhibiting the activity of Factor Xa, which is
widely used for the prophylaxis of thromboembolic disorders. Therapeutic drug monitoring …

In this article, we present a case of apixaban elimination prolonged by 450% in a patient
with coronavirus disease 2019 because of multiple conditions, including drug–drug …

Introduction To identify the potential factors responsible for the individual variability of
dabigatran, we investigated the genetic variations associated with clinical outcomes and …

A bstract Direct oral anticoagulants represent a significant group of drugs used in the
prevention or treatment of venous thromboembolic events and stroke in patients with atrial …